The presence of different markers determines each patient’s individual disease status, i.e., whether the patient has Alzheimer’s pathological change only (Aβ pathology: A+) or AD (Aβ and fibrillar tau pathology: A+T+) [4]. The gene discussed is MAPT; the disease is Alzheimer disease.